Sapeme

Sapreme Technologies is a preclinical-stage biotechnology company based in Utrecht, Netherlands, focused on developing next-generation RNA therapeutics for patients with genetically driven diseases. The company's proprietary Sapreme Platform Technology (SPT) utilizes plant-derived endosomal escape enhancers, specifically glycosylated triterpenoids, to overcome the challenge of endosomal entrapment. This technology enables the efficient delivery of large molecules, such as antisense oligonucleotides (ASOs) and siRNAs, to intracellular targets in both liver and extrahepatic tissues like muscle, heart, and brain. Sapreme is currently advancing an internal pipeline with a lead program in Duchenne muscular dystrophy (DMD) and is actively seeking strategic partnerships to expand the application of its platform across various therapeutic areas.